PMID: 9421617Jan 9, 1998Paper

Granulocyte colony-stimulating factor receptor mutations in severe chronic neutropenia and acute myeloid leukaemia: biological and clinical significance

Baillière's Clinical Haematology
I P Touw

Abstract

Blood cell formation is governed by the haemopoietic growth factors that control the proliferation, maturation and survival of the haemopoietic progenitor cells via activation of receptors expressed on the cell membrane. Most of these receptors share structural features and have been grouped in the haemopoietin or class I receptor superfamily. Recently considerable progress has been made in elucidating the regions critical for the function of these receptors and the signal transduction mechanisms that they activate. Moreover, it has become clear that certain clinical haematological conditions can be linked to specific defects in these receptors. The significance of defects in the receptor for granulocyte colony-stimulating factor (G-CSF) in the pathogenesis of severe congenital neutropenia and acute myeloid leukaemias is discussed.

References

Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J F Bazan
Nov 3, 1995·Science·T NosakaJ N Ihle
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·F DongB Löwenberg
Sep 1, 1995·British Journal of Haematology·M RyanP J Darbyshire
Feb 1, 1995·Trends in Genetics : TIG·J N Ihle, I M Kerr
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·J P DiSantoK Rajewsky
Mar 1, 1993·Cytokine·D Cosman
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A de la ChapelleE Juvonen
Apr 18, 1996·Nature·K TakedaS Akira

❮ Previous
Next ❯

Citations

Sep 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Elaine M SloandNeal S Young
Apr 5, 2018·Blood·Toshiya InabaHirotaka Matsui

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.